Ingalls & Snyder LLC Has $498,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

Ingalls & Snyder LLC trimmed its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 34.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,724 shares of the medical research company's stock after selling 3,463 shares during the period. Ingalls & Snyder LLC's holdings in Edwards Lifesciences were worth $498,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in EW. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences in the 4th quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the 3rd quarter valued at about $32,000. Avior Wealth Management LLC boosted its position in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after buying an additional 308 shares during the last quarter. Finally, JFS Wealth Advisors LLC boosted its position in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock valued at $46,000 after buying an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. The Goldman Sachs Group upped their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price objective for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus price target of $79.95.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the firm's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares of the company's stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 over the last quarter. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded up $0.23 during trading hours on Monday, hitting $76.23. The stock had a trading volume of 3,899,190 shares, compared to its average volume of 4,438,355. The stock's fifty day simple moving average is $72.67 and its 200 day simple moving average is $69.58. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market capitalization of $44.96 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.